Alpha 2.0
Login Register
» Authors » Paul E Sax

Paul E Sax

Explore the profile of Paul E Sax including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 277
Citations 7906
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Pharmacology
Top 10 Co-Authors
Kenneth A Freedberg
Eric S Daar
Rochelle P Walensky
Camlin Tierney
Elena Losina
Milton C Weinstein
A David Paltiel
Grace A McComsey
Rajesh T Gandhi
Edwin DeJesus
Published In
Clin Infect Dis
AIDS Clin Care
J Acquir Immune Defic Syndr
J Watch AIDS Clin Care
J Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
A systematic review and meta-analysis of the effectiveness of remdesivir to treat SARS-CoV-2 infection in hospitalized patients: have the guidelines evolved with the evidence?
Bartoletti M, Mozaffari E, Amin A, Doi Y, Loubet P, Rivera C, et al.
Clin Infect Dis . 2025 Mar; PMID: 40067859
Background: With progressive accumulation of knowledge on SARS-CoV-2 infection clinical management, treatment guidelines recommended several options including remdesivir (RDV), a broad-spectrum antiviral. Given the evolving nature of COVID-19, capturing the...
2.
Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption
Moyle G, Gruber J, Dunbar M, Radtchenko J, Frick A, Marongiu A, et al.
AIDS . 2025 Mar; PMID: 40053475
Objective: Treatment adherence remains critical in maintaining HIV RNA suppression on antiretroviral therapy. High genetic barrier regimens constructed with three long half-life agents may prevent resistance emergence and can be...
3.
Social Media Savvy, It's More Than Just the #Hashtags: How the Use of Social Media in Transplant Infectious Diseases Can Impact the Field and Patients
Harris C, Gupta S, Sax P, Vilchez G, Schwartz I, Jandhyala D, et al.
Transpl Infect Dis . 2024 Dec; 27(1):e14420. PMID: 39692593
Social media provides platforms for transplant infectious diseases (TIDs) clinicians to network, exchange ideas, and educate each other and the broader public. A #TxIDChat on the social media platform X...
4.
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel
Gandhi R, Landovitz R, Sax P, Smith D, Springer S, Gunthard H, et al.
JAMA . 2024 Dec; 333(7):609-628. PMID: 39616604
Importance: New data and new antiretroviral drugs and formulations continue to become available for the prevention and management of HIV infection. Objective: To provide updated recommendations for HIV treatment and...
5.
Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy
Andreatta K, Sax P, Wohl D, DAntoni M, Liu H, Hindman J, et al.
J Antimicrob Chemother . 2024 Nov; 80(1):281-291. PMID: 39556192
Objective: Five Phase 3 bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) clinical studies demonstrated that the efficacy of B/F/TAF was non-inferior to dolutegravir (DTG) + 2 NRTIs. We retrospectively assessed drug adherence and effect...
6.
Long-Acting Cabotegravir Plus Rilpivirine in People with HIV with Adherence Challenges and Viremia: Current Data and Future Directions
Davis J, Rana A, Sax P, Bares S
Clin Infect Dis . 2024 Nov; PMID: 39530595
Long-acting injectable cabotegravir plus rilpivirine (LA CAB/RPV) is currently US Food and Drug Administration (FDA)-approved and HIV treatment guideline-endorsed as a switch strategy for patients with HIV (PWH) who are...
7.
Management of Vulnerable Patients Hospitalized for COVID-19 With Remdesivir: A Retrospective Comparative Effectiveness Study of Mortality in US Hospitals
Mozaffari E, Chandak A, Berry M, Sax P, Loubet P, Doi Y, et al.
Clin Infect Dis . 2024 Oct; 79(Supplement_4):S137-S148. PMID: 39423791
Background: Coronavirus disease 2019 (COVID-19) remains a major public health concern, with continued resurgences of cases and substantial risk of mortality for hospitalized patients. Remdesivir has become standard-of-care for hospitalized...
8.
Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era
Mozaffari E, Chandak A, Gottlieb R, Chima-Melton C, Berry M, Amin A, et al.
Clin Infect Dis . 2024 Oct; 79(Supplement_4):S149-S159. PMID: 39405443
Background: Patients with immunocompromising conditions are at increased risk for coronavirus disease 2019 (COVID-19)-related hospitalizations and deaths. Randomized clinical trials provide limited enrollment, if any, to provide information on the...
9.
Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19
Mozaffari E, Chandak A, Gottlieb R, Chima-Melton C, Berry M, Oppelt T, et al.
Clin Infect Dis . 2024 Sep; 80(1):63-71. PMID: 39302162
Background: Treatment guidelines were developed early in the pandemic when much about coronavirus disease 2019 (COVID-19) was unknown. Given the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), real-world...
10.
Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial
Masheto G, Brummel S, Ziemba L, Shepherd J, Mbengeranwa T, Igawa L, et al.
J Acquir Immune Defic Syndr . 2024 Sep; 97(2):172-179. PMID: 39250651
Background: Safety data from randomized trials of antiretrovirals in pregnancy are scarce. We evaluated maternal bone and renal data from the International Maternal Pediatric Adolescent AIDS Clinical Trials Network 2010...